See the DrugPatentWatch profile for canakinumab

At this time, there are no approved biosimilars for canakinumab, a human monoclonal antibody used to treat certain auto-inflammatory diseases. Therefore, no company leads in canakinumab biosimilar development and sales. Canakinumab is currently marketed under the brand name Ilaris by Novartis, and its patents are set to expire in 2024 in the United States [1]. Once the patents expire, it is expected that biosimilar developers will enter the market.

Biosimilars are follow-on versions of already approved biologic drugs, and they are designed to have similar safety, purity, and potency as the reference biologic drug [2]. Biosimilars are typically less expensive than the reference biologic drug, making them more accessible to patients.

According to DrugPatentWatch.com, there are several companies with pending patent applications for canakinumab biosimilars [3]. These companies include but are not limited to:

1. Celltrion Healthcare Co., Ltd.
2. STADA Arzneimittel AG
3. Biocon Limited
4. Intas Pharmaceuticals Ltd.
5. Dr. Reddy's Laboratories Ltd.

It is important to note that the development and approval of biosimilars can be a lengthy and complex process, and it is not yet clear which, if any, of these companies will successfully bring a canakinumab biosimilar to market.

In summary, there are currently no approved biosimilars for canakinumab, and it is not yet clear which company will lead in canakinumab biosimilar development and sales. However, several companies have pending patent applications for canakinumab biosimilars, and it is expected that the market will become more competitive once the patents for the reference biologic drug expire.

Sources:

1. Novartis. (2021). Ilaris (canakinumab) [Prescribing information]. Retrieved from <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/ilaris.pdf>
2. U.S. Food and Drug Administration. (2021). Biosimilars: Information for healthcare providers. Retrieved from <https://www.fda.gov/drugs/biosimilars/biosimilars-information-healthcare-providers>
3. DrugPatentWatch.com. (2022). Canakinumab. Retrieved from <https://www.drugpatentwatch.com/drugs/canakinumab>